Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Miruna Stanciu"'
Autor:
Andreea PAROSANU, Ana-Maria POPA, Cristian IACIU, Mihaela OLARU, Cristina ORLOV-SLAVU, Horia COTAN, Miruna STANCIU, Radu VRABIE, Cornelia NITIPIR
Publikováno v:
Modern Medicine, Vol 29, Iss 1, Pp 93-97 (2022)
Paraneoplastic syndromes of the nervous system are rare disorders, strongly linked with lung cancer. This report aims to explore the challenges in the diagnosis and treatment of a patient with early-stage small cell lung cancer and neurological manif
Externí odkaz:
https://doaj.org/article/ec6491a43f004bd9973907a5016d827e
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 1111 (2024)
The management of renal cell carcinoma (RCC) has been revolutionized over the past two decades with several practice-changing treatments. Treatment for RCC often requires a multimodal approach: Local treatment, such as surgery or ablation, is typical
Externí odkaz:
https://doaj.org/article/8545389781424c5cbc4e4d7a1e500a72
Autor:
Catalin Baston, Andreea Ioana Parosanu, Mihaela Mihai, Oana Moldoveanu, Ioana Miruna Stanciu, Cornelia Nitipir
Publikováno v:
Diagnostics, Vol 14, Iss 5, p 553 (2024)
Tumor-to-tumor metastasis (TTM) is a rare phenomenon documented in patients with multiple primary cancers. This condition is defined as a metastasis between two true primary tumors. The most frequently reported recipient tumor is renal cell carcinoma
Externí odkaz:
https://doaj.org/article/d23d71780ef64a5daf0ea9cecec5fa48
Autor:
Andreea Ioana Parosanu, Cristina Florina Pirlog, Cristina Orlov Slavu, Ioana Miruna Stanciu, Horia-Teodor Cotan, Radu Constantin Vrabie, Ana-Maria Popa, Mihaela Olaru, Cristian Iaciu, Lucian Ioan Bratu, Ionut Florian Baicoianu, Oana Moldoveanu, Catalin Baston, Cornelia Nițipir
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 2457-2464 (2023)
Background: Metastatic renal cell carcinoma (mRCC) is an aggressive cancer characterised by an increased recurrence rate and an inadequate response to treatment. This study aimed to investigate the importance of the neutrophil-to-lymphocyte ratio (NL
Externí odkaz:
https://doaj.org/article/0895789e72fe44cf8e12d3a27289df91
Publikováno v:
Biomolecules, Vol 13, Iss 9, p 1422 (2023)
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have transformed the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer over the last decade. These inhibitors are currently
Externí odkaz:
https://doaj.org/article/ac584e7b9e3b4b2dafbea08cbdbce074
Autor:
Andreea Ioana Parosanu, Catalin Baston, Ioana Miruna Stanciu, Cristina Florina Parlog, Cornelia Nitipir
Publikováno v:
Diagnostics, Vol 13, Iss 14, p 2430 (2023)
Background: Over the past few years, significant advancements have been achieved in the front-line treatment of metastatic renal cell carcinomas (mRCCs). However, most patients will eventually encounter disease progression during this front-line trea
Externí odkaz:
https://doaj.org/article/d1dcada7c08b4a64b8bae88dbf26557f
Autor:
Ioana-Miruna Stanciu, Cristina Florina Pirlog, Andrei-Wilhelm Anghel, Andreea Ioana Parosanu, Cristina Mihaela Olaru, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Radu Constantin Vrabie, Cornelia Nitipir
Publikováno v:
Medicina, Vol 59, Iss 4, p 696 (2023)
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Followi
Externí odkaz:
https://doaj.org/article/3937aff8b0fd4bc7a9b4c3be4d446f1b
Autor:
Ioana-Miruna Stanciu, Andreea Ioana Parosanu, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Cristina Mihaela Olaru, Cristina Florina Pirlog, Radu Constantin Vrabie, Cornelia Nitipir
Publikováno v:
Diagnostics, Vol 13, Iss 5, p 987 (2023)
The latest and newest discoveries for advanced and metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer are the three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in associati
Externí odkaz:
https://doaj.org/article/6c9da4fa657d4d3eb1982d2cad5f926e
Autor:
Andreea Parosanu, Miruna Stanciu, Cristina Parlog, Cristina Orlov, Mihaela Olaru, Ana Maria Popa, Horia Cotan, Radu Vrabie, Cristian Iaciu, Oana Moldoveanu, Catalin Baston, Cornelia Nitipir
Publikováno v:
International Journal of Innovative Research in Medical Science. 7:743-745
Background: The incidence of metastatic renal cell carcinoma has steadily increased. Therefore, it is essential to identify precise biomarkers to predict survival and improve clinical care. Objectives: This study aimed to evaluate potential prognosti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a02cf0405230701eaab48ca3256f451
https://doi.org/10.23958/ijirms/vol07-i12/1578
https://doi.org/10.23958/ijirms/vol07-i12/1578
Autor:
Andreea Parosanu, Ioana Miruna Stanciu, Cristina Pirlog, Cristina Orlov Slavu, Horia Cotan, Cristian Iaciu, Ana Maria Popa, Mihaela Olaru, Oana Moldoveanu, Baston Catalin, Cornelia Nitipir
Publikováno v:
Cureus. 14(10)
With recent advances in oncology, immune checkpoint inhibitors (ICIs) have become a milestone in immuno-oncology. Unfortunately, although ICIs have demonstrated improved clinical efficacy in a broad spectrum of cancers, many patients do not respond t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931b95fdb74188b0eb3d1b681ae0aced
https://pubmed.ncbi.nlm.nih.gov/36451642
https://pubmed.ncbi.nlm.nih.gov/36451642